1. 587 Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models. (10th December 2020) Authors: Jenkins, Kurt; Johnson, Parker; Zhang, Minjie; Guzman, Wilson; Eskiocak, Ugur; McLaughlin, Megan; O'Toole, Caitlin; Pederzoli-Ribeil, Magali; Park, Miso; Williams, John; Karow, Margaret; O'Neil, Jennifer; Clackson, Timothy; O'Hagan, Ronan Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Issue 12 (December 2016) Authors: Gettinger, Scott N; Bazhenova, Lyudmila A; Langer, Corey J; Salgia, Ravi; Gold, Kathryn A; Rosell, Rafael; Shaw, Alice T; Weiss, Glen J; Tugnait, Meera; Narasimhan, Narayana I; Dorer, David J; Kerstein, David; Rivera, Victor M; Clackson, Timothy; Haluska, Frank G; Camidge, David Ross Journal: Lancet oncology Issue: Volume 17:Issue 12(2016:Dec.) Page Start: 1683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Issue 5 (May 2016) Authors: Lipton, Jeffrey H; Chuah, Charles; Guerci-Bresler, Agnès; Rosti, Gianantonio; Simpson, David; Assouline, Sarit; Etienne, Gabriel; Nicolini, Franck E; le Coutre, Philipp; Clark, Richard E; Stenke, Leif; Andorsky, David; Oehler, Vivian; Lustgarten, Stephanie; Rivera, Victor M; Clackson, Timothy; Ha... Journal: Lancet oncology Issue: Volume 17:Issue 5(2016:May) Page Start: 612 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗